HIV: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CCR5 1
• CXCR4 0
• PD-1 2
• IL-15 1
• JAK 1
• STING 0
• GLP-1 2
• IL-17 0
• PD-L1 1
• TNF 0
• IL-6 0
• mTOR 1
• TP53 0
• NLRP3 0
• SGLT2 2
• STAT3 0
• AKT 0
• APOL1 0
• PCSK9 0
• PPAR 0
• CD40 1
• NRF2 0
• PI3K 0
• BCL-2 2
• CD19 1
• ERK 0
• HDAC 0
• HIF-1 0
• APOE 0
• BRD4 0
• FOXP3 0
• HSP90 0
• MAPK 0
• METTL3 0
• AMPK 0
• ATM 0
• BDNF 0
• CD20 0
• CD38 0
• CTNNB1 0
• FLT3 0
• HMGB1 0
• IL-1 0
• MET 0
• NMDA 0
• TIGIT 0
• VEGF 0
• ACE2 0
• ALK 0
• ANGPTL3 0
• AQP4 0
• BRCA1 0
• BRCA2 0
• BTK 0
• CFTR 0
• COX-2 0
• CTLA-4 0
• DPP-4 0
• FTO 0
• G6PD 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · F30

  Development and Implementation of a Cost-Effective Diagnostic Algorithm to Reduce AIDS-Related Deaths among Hospitalized People with Advanced HIV Disease

  University of Minnesota· Minneapolis, United States· US$55,114 awarded in fiscal year 2026· until Oct 2030

• NIH NIAID · F32

  ENV GLYCOPROTEIN INCORPORATION AT HIV-1 ASSEMBLY SITES: STERIC REGULATION DRIVEN BY THE LONG CYTOPLASMIC TAIL

  University of Denver (Colorado Seminary)· Denver, United States· US$89,476 awarded in fiscal year 2026· until Oct 2027

• NIH NIAID · F31

  Human retrovirus assembly interplay with the actin cortex

  University of Minnesota· Minneapolis, United States· US$48,621 awarded in fiscal year 2026· until Sept 2029

• NIH NIDA · K24

  Mentoring in community-engaged research to address HIV and substance use

  Emory University· Atlanta, United States· US$217,483 awarded in fiscal year 2026· until Aug 2031

• NIH OD · N01

  Prototype Pediatric Oral Dissolving Films for the Prevention of Tuberculosis (TB)

  Advanced Bioscience Laboratories, Inc.· Rockville, United States· US$2,559,631 awarded in fiscal year 2026· until Sept 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Comparative and entangled histories of AIDS care in Austria and Slovenia, 1980s–2000s (AIDScare)

  Universitaet Graz· Graz, Austria· EU contribution €230,185· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Immunometabolic Reprogramming via a Gut-derived Organoid Platform (IRGOP)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €247,553· until Dec 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  BRIDGING RESERVOIR SCIENCE, INTEGRATED DRUG DISCOVERY, BIG DATA ANALYTICS, ARTIFICIAL INTELLIGENCE AND EPIDEMIOLOGY (BRIDGE-HIV)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Netherlands· EU contribution €1,703,400· until Sept 2030· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-CSA

  West African Network of Excellence for TB, AIDS and Malaria (WANETAM-4)

  European & Developing Countries Clinical Trials Partnership· Den Haag, Netherlands· EU contribution €12,751,885· until Jun 2031· 14 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Defining the Landscape of Transcriptional Activity during HIV-1 Infection (DELTA-HIV)

  King's College London· London, United Kingdom· EU contribution €260,348· until May 2028

10 of 2,889 running projects, newest first. Listed amounts together: US$2.2bn + €81.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 22
• Organoids 6
• Mendelian Randomization Analysis 7
• CRISPR-Cas Systems 27
• Gene Expression Profiling 62
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 15
• Exome Sequencing 3
• Proteomics 37
• Metabolomics 33
• Mass Spectrometry 16
• Flow Cytometry 45
• Immunohistochemistry 15
• Xenograft Model Antitumor Assays 3
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 79
• Machine Learning 72
• Deep Learning 21
• Cohort Studies 426
• Genome-Wide Association Study 20

• Sphenoidal Meningioma with Focal Seizures Masquerading as Immune Reconstitution Inflammatory Syndrome in HIV Patient.

  Niger Postgrad Med J, Nov 2026

• Evidence that intrinsic brain connectivity moderates the association between gait and neurocognitive function in people living with HIV.

  J Neurovirol, Oct 2026

• Case Report: Multiple brain abscess-like lesions with concurrent detection of Nocardia amamiensis and Leishmania infantum in cerebrospinal fluid.

  Front Immunol, Sept 2026

• Post-treatment serologic, cerebrospinal fluid, MRI, and salivary antibody responses in HIV-negative neurosyphilis: a retrospective study.

  Front Neurol, Sept 2026

• The GrimAge clock corresponds to brain ageing and social determinants of health in people with HIV.

  EBioMedicine, Sept 2026

• Brain MR elastography metrics associated with alterations in learning and memory in people with HIV.

  Sci Rep, Sept 2026

• Acute ischemic stroke revealing cryptococcal meningitis in an HIV-infected patient with a relatively preserved CD4 count: a case report.

  Neurol Sci, Sept 2026

• Impact of cannabis use on white matter hyperintensities in adults with and without chronic HIV disease.

  J Neurovirol, Aug 2026

• From seropositivity to neurosyphilis: clinical spectrum and diagnostic classification in hospitalized neurology patients: a 16-year retrospective study.

  Front Neurol, Aug 2026

• Multiple cranial neuropathy secondary to tuberculous meningitis and intracranial tuberculoma in an adolescent.

  Biomedica, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.